NICE's final yea and nay to to Lucentis and Avastin
This article was originally published in Scrip
Roche's VEGF receptor agonist Avastin (bevacizumab) for advanced ovarian cancer is still too expensive for routine use on the National Health Service in England and Wales, says NICE, the health technology appraisal institute. But with the help of a patient access scheme, Novartis helped persuade the institute that its VEGF drug, Lucentis (ranibizumab), is a good use of NHS funds.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.